



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

9 November 2023

EMA/PRAC/464397/2023

Human Medicines Evaluation Division

List of nationally authorised medicinal products for Variation outcome

Active substance(s): furosemide / spironolactone

Procedure no.: PSUSA/00001493/202303

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands

Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us

Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union



© European Medicines Agency, 2023. Reproduction is authorised provided the source is acknowledged.

Product Name (in authorisation country)	MRP/DCP Authorisation number	National Authorisation Number	MAH of product in the member state	Member State where product is authorised
Spiro comp. forte-ratiopharm® 100 mg/20 mg Filmdabletten	not available	0687/05/09/8248	RATIOPHARM GMBH	LU
Lasilacton 20 mg/100 mg Kapseln	not available	17.056	SANOFI-AVENTIS GMBH OSTERREICH	AT
Lasilacton 20 mg/100 mg Kapseln	not available	17.056	SANOFI-AVENTIS GMBH OSTERREICH	AT
SPIROFUR 50 mg + 20 mg capsule rigide	not available	023749056	BRUNO FARMACEUTICI	IT
SPIROFUR 50 mg + 20 mg capsule rigide	not available	023749017	BRUNO FARMACEUTICI	IT
Lasilacton 20 mg/50 mg Kapseln	not available	17.055	SANOFI-AVENTIS GMBH OSTERREICH	AT
Lasilacton 20 mg/50 mg Kapseln	not available	17.055	SANOFI-AVENTIS GMBH OSTERREICH	AT
LASITONE	not available	023770011	SANOFI S.R.L.	IT
Spiro comp. forte-ratiopharm® 100 mg/20 mg Filmdabletten	not available	2153.01.00	RATIOPHARM GMBH	DE